There are 437 resources available
Characteristics and treatment outcomes of screening-detected early NSCLC
Presenter: Witold Rzyman
Session: Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC?
Resources:
Slides
Webcast
Current standard of care in adjuvant / neoadjuvant therapy of operable NSCLC
Presenter: Heather Wakelee
Session: Adjuvant / neoadjuvant therapy of operable NSCLC in 2023
Resources:
Slides
Webcast
Opportunities for immunotherapy in stage I NSCLC
Presenter: Silvia Novello
Session: Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC?
Resources:
Slides
Webcast
Expanding our horizons: Novel frontline approaches in EGFR-mutant NSCLC
Presenter: Nicolas Girard
Session: Janssen Pharmaceutica N.V. - Transforming treatment approaches for patients with EGFR-mutant NSCLC
Resources:
Webcast
1497P - Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in untreated advanced non-small-cell lung cancer
Presenter: Yawen Bin
Session: Poster session 21
Strategies for overcoming EGFR resistance in NSCLC patient management
Presenter: Antonio Passaro
Session: Janssen Pharmaceutica N.V. - Transforming treatment approaches for patients with EGFR-mutant NSCLC
Resources:
Webcast
Current and future directions for EGFR exon 20 insertion mutations in NSCLC
Presenter: Joshua Sabari
Session: Janssen Pharmaceutica N.V. - Transforming treatment approaches for patients with EGFR-mutant NSCLC
Resources:
Webcast
2264P - Proteomics-based phenotypic classification of non-smallcell lung cancer
Presenter: Olena Berkovska
Session: Poster session 08
1241P - Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics
Presenter: Kai He
Session: Poster session 14
Emerging data on the role of ADCs in the clinical care pathways for advanced NSCLC patients
Presenter: Pasi Jänne
Session: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Resources:
Slides
Webcast